OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

INDIVIOR PLC DL 0,50/  GB00BN4HT335  /

Lang & Schwarz
30/07/2024  07:44:00 Chg. 0.000 Volume Bid07:44:00 Ask07:44:00 Market Capitalization Dividend Y. P/E Ratio
11.900EUR 0.00% -
Turnover: -		 11.900Bid Size: - 12.200Ask Size: - 1.62 bill.EUR - -
GlobeNewswire 01/07 Addex Shareholders Approve All Resolutions at Annual General Meeting
GlobeNewswire 06/06 Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05/06 Addex Convenes Annual General Meeting 2024
GlobeNewswire 31/05 Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire 08/05 Addex to Present at Bio€quity Europe 2024
GlobeNewswire 29/04 Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
GlobeNewswire 19/04 Addex to Present at the Swiss Biotech Day 2024
GlobeNewswire 18/04 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 11/04 Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire 03/04 Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire 14/03 Addex to Present at the Bio-Europe Spring 2024 Conference
GlobeNewswire 05/03 Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire 31/01 Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire 18/01 Adial Announces Appointment of Tony Goodman as Chief Operating Officer
GlobeNewswire 09/01 Addex to Present at the Swiss Equities Baader Conference
GlobeNewswire 05/01 Addex to Present at Biotech Showcase™ 2024
GlobeNewswire 14/12/2023 Addex Creates Treasury Shares
GlobeNewswire 29/11/2023 Addex Reports Q3 2023 Financial Results and Provides Corporate Update
GlobeNewswire 28/11/2023 Addex Convenes Extraordinary General Meeting
GlobeNewswire 23/11/2023 Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
GlobeNewswire 14/11/2023 Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
GlobeNewswire 08/11/2023 Addex Regains Nasdaq Listing Compliance
GlobeNewswire 02/11/2023 Addex Announces Participation in the Bio-Europe 2023 Conference
Newsfile Corp 31/10/2023 Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland
GlobeNewswire 20/10/2023 Addex Completes ADS Ratio Change